Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%

MT Newswires Live

02/09

Pacific Edge (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.

The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.

The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.

The company's Kiwi shares rose nearly 5% in recent Monday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610503981"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610503981\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610503981?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610503981","market":"sg","top_or_hot":-1,"title":"Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.</p><p>The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.</p><p>The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.</p><p>The company's Kiwi shares rose nearly 5% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge Confirms Novitas to Review Urine Biomarkers for Hematuria; Shares Up 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-09 06:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.</p><p>The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.</p><p>The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.</p><p>The company's Kiwi shares rose nearly 5% in recent Monday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAC","symbol_name":"卡姆登國家銀行","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610503981","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610503981","pubTimestamp":1770591050,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee  meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.The company's Kiwi shares rose nearly 5% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAC":"卡姆登国家银行","BK7067":"生物科技","PEB.AU":"PACIFIC EDGE LTD","BK8033":"生物科技","BK4211":"区域性银行","PEB.NZ":"Pacific Edge Limited Ordinary Shares"},"translate_title":"Pacific Edge确认Novitas将审查血尿的尿液生物标志物；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.NZ":1.5,"PEB.AU":1,"CAC":1},"content_text":"Pacific Edge (NZE:PEB, ASX:PEB) said Medicare Administrative Contractor, Novitas, will hold a Contractor Advisory Committee (CAC) meeting on Feb. 19 to evaluate clinical evidence supporting the use of its urine biomarkers for patients with hematuria, according to a Monday filing with the Australian and New Zealand bourses.The committee's opinions are likely to influence Novitas' draft local coverage determination regarding Medicare reimbursement for Cxbladder, per the filing.The company expects to enter a trading halt ahead of the CAC meeting that would remain in place until it provides investors with an update on the discussions, the filing added.The company's Kiwi shares rose nearly 5% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}